Gadolinium-based contrast agents: why nephrologists need to be concerned

Area of Science:

• Radiology and Medical Imaging
• Nephrology
• Toxicology

Background:

• Gadolinium-based contrast agents (GBCAs) are widely used in medical imaging.
• Adverse events, particularly nephrogenic systemic fibrosis (NSF), have been linked to GBCAs.
• The understanding of GBCA-induced adverse events is evolving beyond renal impairment.

Purpose of the Study:

• To review the current understanding of GBCA-induced adverse events.
• To highlight that NSF is triggered by GBCAs, with kidney impairment as a risk factor, not the sole cause.
• To explore the occurrence of GBCA-related symptoms in patients with normal renal function.

Main Methods:

• Literature review of studies on gadolinium-based contrast agents and adverse events.
• Analysis of reported cases of nephrogenic systemic fibrosis.
• Examination of physiological reactions in patients with and without renal impairment.

Main Results:

• Nephrogenic systemic fibrosis is triggered by gadolinium-based contrast agents, not solely by renal impairment.
• Adverse events and NSF manifestations can occur years after exposure.
• Similar symptom clusters are observed in patients with normal renal function, indicating undefined physiological reactions.

Conclusions:

• Gadolinium-based contrast agents should be used with extreme caution.
• Renal insufficiency is not the sole determinant for GBCA-induced adverse events.
• Further research is needed to define the undefined physiological reactions to GBCAs.